REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
A phase 2/3 trial of Luveltamab tazevibulin, Pegfilgrastim, Gemcitabine, Paclitaxel / nab-paclitaxel, Pegylated liposomal doxorubicin and Topotecan in Ovarian cancer and Platinum-resistant ovarian cancer, run by Sutro Biopharma, Inc., recorded as terminated on the registry.
Overview
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 is a phase 2/3 interventional study registered as NCT05870748 by Sutro Biopharma, Inc., with 600 participants recorded, started 2023-07-12 and due to reach its primary completion in 2025-08-26. Interventions recorded: Luveltamab tazevibulin, Pegfilgrastim, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan. Conditions recorded: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer.
Linked to the drug Luveltamab tazevibulin because the registry names it among its interventions and Ovarian cancer and Platinum-resistant ovarian cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
Shares Pegylated liposomal doxorubicin, Topotecan, Platinum-resistant ovarian cancer, Gemcitabine and the tag pipeline.
- TrialTrial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
- TrialMirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer
Shares Pegylated liposomal doxorubicin, Gemcitabine, Ovarian cancer and the tag pipeline.
- TrialCancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
- TrialFiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
- Trialp53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
Shares Pegylated liposomal doxorubicin, Ovarian cancer and the tag pipeline.
- TrialRandomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer
Shares Pegfilgrastim, Paclitaxel / nab-paclitaxel and the tag pipeline.
- TrialChemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer
Shares Paclitaxel / nab-paclitaxel, Ovarian cancer and the tag pipeline.